

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_80456
Title of the Manuscript:	Medicinal Properties of Terminalia Arjuna: A Review
Type of the Article	Review Article

### General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

[Review Form 1.6](#)

**PART 1:** Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<p>MS_JPRI_80456</p> <p>Title: Medicinal Properties of Terminalia Arjuna: A Review</p> <p>This is a very interesting manuscript. However, in order to be published, it is recommended to modify the following few things.</p> <ol style="list-style-type: none"><li>1. This review paper is about the medicinal properties of <i>T. arjuna</i>. According to the PubMed survey, there are more than 1,000 papers and 100 review papers about <i>T. arjuna</i>. To be a new review paper on <i>T. arjuna</i>, which has been studied a lot for a long time, the completeness is not enough, so it is better to rewrite it..</li><li>2. Table 2 summarized the main phytochemical components contained in <i>T. arjuna</i>. However, some of the components listed in Table 2 are missing references. For example, there are seven references in PubMed to casuarinin contained in <i>T. arjuna</i>. Therefore, it is necessary to re-examine the references for the ingredients cited in Table 2.</li><li>3. Since the name of <i>T. arjuna</i> is divided into a genus name and a species name, I think that it cannot be written as <i>T. ARJUNA</i>.</li><li>4. About abbreviations: The use of abbreviations in the abstract is used separately from the text. That is, it is not necessary to specify abbreviations for abbreviations that are not used repeatedly in the abstract. Define CADs and CHF. And, after specifying the full name and abbreviation of a specific term from the introduction part, you can use the abbreviation to the conclusion part.</li><li>5. English: The manuscript has numerous grammatical and typographical errors that should be corrected. It is absolutely necessary to get a proofreading from a professional English language-editor.</li></ol>	<p>Dear Editor,</p> <p>I made corrections as per your suggestions.</p>
<b>Minor</b> REVISION comments	<ol style="list-style-type: none"><li>6. Units are written with a space after the number. There are also several typos for this matter. Examples: 12.5µg/disc should be 12.5 µg/disc. IC50 should be IC<sub>50</sub>.</li><li>7. Reference section: Author should consult and peruse carefully recent issues of the journal, <b><i>Journal of Pharmaceutical Research International</i></b>, for format and style. The first letter of the title must be in upper case, and the rest must be in lower case.</li></ol>	
<b>Optional/General</b> comments	<p><b><u>Overall, the manuscript can be considered to publication after major revision as indicated above.</u></b></p>	

Review Form 1.6

**PART 2:**

	Reviewer’s comment	Author’s comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	